Meanwhile, the pharma sector in India could witness an immediate loss of Rs 1,000 crore due to the government ban on combination drugs that include cough syrups, anti-diabetic medicines and flu treatments, according to media reports. In this space, Lupin, Sun Pharma, Cipla and Dr Reddy’s Lab are down 0.2%-1.6%.
Overseas, the US central bank, as expected, kept the interest rates unchanged trimming forecasts for hike in short-term rates planned for this year.
By 2:00 pm, the S&P BSE Sensex was higher by 176 points at 24,858 and the Nifty50 climbed 67 points at 7,566.
Top gainers in the Sensex pack include GAIL, ONGC, Bharti Airtel, Adani Ports and ICICI Bank up 2%-4.5%.
STOCK ACTION
__________________
(updated at 11:05 am)
Markets have trimmed gains in the late morning trades as losses in healthcare shares weighed on the sentiment. However, the benchmark indices continue to remain positive after US central bank, as expected, kept the interest rates unchanged trimming forecasts for hike in short-term rates planned for this year amid rise in oil prices and strength in global equities.
Five healthcare majors including Procter and Gamble, Glenmark and Reckitt Benckiser on Wednesday got interim relief from the Delhi high court, which stayed till March 21 the ban imposed by the government on sale of some of their fixed dose combination (FDC) medicines. P&G and Glenmark are trading with marginal gains.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)